Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
Pancreatic Cancer|Cancer of the Pancreas|Pancreas Cancer
DRUG: CDX-301|DRUG: CDX-1140|PROCEDURE: Research blood draw
Amount of Intratumoral Conventional Dendritic Cells (cDCs), At time of surgery (estimated to be between day 8 and day 20)
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.